Abstract: The present disclosure is concerned with Clofarabine analogs for the treatment of various cancers such as, for example, sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, bladder cancer, thyroid cancer, testicular cancer, pancreatic cancer, endometrial cancer, melanomas, gliomas, leukemias, lymphomas, chronic myeloproliferative disorders, myelodysplastic syndromes, myeloproliferative neoplasms, and plasma cell neoplasms (myelomas). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: A citrine pleurotus (Pleurotus citrinopileatus) polysaccharide and application thereof are provided, which relate to the field of natural product development and utilization. The citrine pleurotus polysaccharide includes xylose, glucose, galactose, glucuronic acid, fucose, fructose and arabinose. The citrine pleurotus polysaccharide can be applied in preparing drugs for treating sarcopenia caused by cancers. It is demonstrated that the polysaccharide of citrine pleurotus may increase a body weight and a spleen weight, restore morphology, number and density of muscle fibers, reduce inflammatory response and decrease expressions of signature proteins of Atrogin-1 and MuRF-1 for sarcopenia, and alleviate symptoms of tumor-induced sarcopenia in mice with colon cancer cachexia. New effects of polysaccharides of citrine pleurotus are discovered, which provides new ideas for exploitating the citrine pleurotus and treating the sarcopenia caused by cancers.

Abstract: The subject invention pertains to methods for producing novel occidiofungin analogues lacking xylose (OF-?xyl analogue). OF-?xyl analogues can contain aldehyde, amine, triazole, or hydrazones. The aldehyde, amine, triazole or hydrazone containing analogues of OF-?xyl can be further modified by substitution with additional functional groups. Various OF-?xyl analogues described herein have reduced inflammation and toxicity and superior pharmacological properties compared to the natural occidiofungins. Accordingly, certain embodiments of the invention provide methods of treating or preventing fungal infections by administering to the subjects in need thereof the OF-?xyl analogues described herein.

Abstract: Embodiments of the present disclosure relate to lipid-PEGylated solid support and phosphoramidites derivatives, methods for preparing the same, and their uses in the delivery of oligonucleotide drugs to the cellular targets.

Abstract: A hydrocolloid or aqueous solution comprising a poly alpha-1,3-glucan ether compound is disclosed having a viscosity of at least about 10 centipoise (cPs). The poly alpha-1,3-glucan ether compound in these compositions has a degree of substitution of about 0.05 to about 3.0. Also disclosed is a method for increasing the viscosity of a hydrocolloid or aqueous composition using a poly alpha-1,3-glucan ether compound.

Abstract: Smad3 inhibitor compounds, specifically a compound of Formula 1 or Formula 2, or a pharmaceutically acceptable salt thereof, and its use in treating or preventing cell proliferation or cancer in a subject are provided.

Abstract: The present invention provides, among other things, methods for purifying mRNA based on normal flow filtration for therapeutic use.

Abstract: Described herein are quinoline compounds useful for, among other things, inhibition of the proteasome and for treatment of cancer and inflammation.

Abstract: The invention relates to compounds of formula (I) and their use in eliciting a pro-Thl7 immune response. Further provided are methods of production of said compounds. (Formula I) wherein m is an integer between 4 and 13; n is an integer between 4 and 13; x is an integer between 4 and 13; y is an integer between 4 and 13.

Abstract: A resin composition is provided that comprises a resin and a phosphorus-based flame retardant. The resin includes a ?-1,3-glucan derivative resin having a main chain having a structure represented by the following structural formula (1): where each of Rs is independently a hydrogen atom or an alkylcarbonyl group, at least one of Rs is an alkylcarbonyl group, and n is a natural number. The phosphorus-based flame retardant has an average particle diameter of 5 ?m or less in the resin.

Abstract: The present disclosure relates to compounds for RNA capping and uses thereof, which belong to the technical field of genetic engineering. Compounds of formula I can result in high levels of capping efficiency, and the capped mRNA exhibits a high transcription level and increased expression.

Abstract: Compounds that activate pyruvate kinase R can be used for the treatment of sickle cell disease (SCD). Methods and compositions for the treatment of SCD are provided herein, including a therapeutic compound designated as Compound 1.

Abstract: The present invention relates to a composition comprising at least one inhibitor of the enzymatic complex conjugating ubiquitin Ubc13/Uev1a and at least one anti-hypertensive agent inhibiting the renin-angiotensin-aldosterone system and/or a hypoglycemic agent. Medical uses and pharmaceutical compositions comprising this composition also fall within the scope of the present invention. In particular, this composition can be used for the treatment or prevention of the renal fibrotic damage, in particular in patients suffering from diabetes.

Abstract: Therapeutic treatments for a disease such as a cancer are disclosed, including pharmaceutical compositions and methods of using pharmaceutical compositions for treating the cancer wherein the cancer cells overexpress arginine methyltransferase CARM1. In some embodiments, the therapeutic treatments disclosed include methods comprising the step of administering a therapeutically effective dose of an enhancer of zeste homolog 2 (EZH2) inhibitor to a subject, including a human subject, wherein the cancer cells of the subject overexpress arginine methyltransferase CARM1 and a PARP inhibitor. In some embodiments, the EZH2 inhibitors are administered in conjunction with platinum-based antineoplastic drugs.

Abstract: A water soluble dietary fibre composition and use thereof is disclosed. The composition comprises: (a) partially hydrolysed and re-polymerized starch, and (b) partially hydrolysed Guar gum.

Abstract: Provided are methods of treating urothelial carcinomas of the lower tract comprising administering comprising administering gemcitabine continuously and locally to the bladder of an individual in an induction therapy and/or maintenance therapy.

Abstract: The present invention provides compounds of Formula (I): wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).

Abstract: Disclosed are compounds of Formula (I) Formula (I) N-oxides, or salts thereof, wherein G1, G2, L, R1a, R1b, R4, R5, n, m, x, and y are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Abstract: Methods of synthesizing chondroitin sulfate oligosaccharides are provided. Enzymatic schematic approaches to synthesizing structurally defined homogenous chondroitin sulfate oligosaccharides at high yields are provided. Synthetic chondroitin sulfate oligosaccharides ranging from 3-mers to 15-mers are provided.

Abstract: Described are niclosamide analogue compounds, pharmaceutical compositions thereof, and method of using the corner pounds and compositions for treating a disease associated with dysregulation of the Wnt/Frizzled signaling pathway, such as cancer, fatty liver, antibiotic resistance, and viral infection. The disclosed compounds and compositions may also be used for modulating mitochondrial function and for treating certain non-cancer diseases and/or diorders, such as diabetes, fibrotic disease, primary sclerosing cholangitis.